Grove Bank & Trust’s Alnylam Pharmaceuticals ALNY Stock Holding History

Grove Bank & Trust’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$4.93K	Buy	20 +6	+43%	+$1.53K	﹤0.01%	741
2026 Q2	$4.21K	Sell	14 -28	-67%	-$8.45K	﹤0.01%	749
2026 Q1	$13.9K	Buy	42 +33	+367%	+$11.2K	﹤0.01%	583
2025 Q4	$3.58K	Buy	+9	New	+$3.98K	﹤0.01%	761
2023 Q2	–	Sell	-6	Closed	-$1.2K	–	639
2023 Q1	$1.2K	Buy	+6	New	+$1.26K	﹤0.01%	688

Other funds holding ALNY

MSV

MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return

LJHT

Laurie J. Hall Trustee $314M AUM 27.43% 1-Year Est. Return

EFG

Everhart Financial Group Dublin, Ohio $1.62B AUM 25.73% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

CPBTD

Central Pacific Bank - Trust Division Honolulu, Hawaii $952M AUM 25.15% 1-Year Est. Return

MPWT

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

BFS

Burkett Financial Services Rock Hill, South Carolina $331M AUM 14.93% 1-Year Est. Return

Grove Bank & Trust's ALNY Position: Q3 2026 in Review

Grove Bank & Trust increased its Alnylam Pharmaceuticals (ALNY) stake by 43% in Q3 2026, buying an estimated $1.53K and bringing the position to 20 shares worth $4.93K. The position accounts for ﹤0.01% of the portfolio, ranked #741.

Grove Bank & Trust first reported a position in ALNY in Q1 2023 and has held it in 5 quarters since. The position peaked at $13.9K in Q1 2026. 19 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

Grove Bank & Trust held 20 shares of Alnylam Pharmaceuticals worth $4.93K as of Q3 2026.
Grove Bank & Trust bought 6 Alnylam Pharmaceuticals shares in Q3 2026, an estimated $1.53K.
Alnylam Pharmaceuticals made up ﹤0.01% of Grove Bank & Trust's portfolio in Q3 2026, its #741 holding.
Grove Bank & Trust first reported a position in Alnylam Pharmaceuticals in Q1 2023 and has held it in 5 quarters since.
Grove Bank & Trust's Alnylam Pharmaceuticals position peaked at $13.9K in Q1 2026.
19 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on Grove Bank & Trust's 13F filing for Q3 2026, filed 8 Oct 2026.